15.46
price up icon1.24%   0.19
after-market 시간 외 거래: 15.25 -0.21 -1.36%
loading

Urogen Pharma Ltd 주식(URGN)의 최신 뉴스

pulisher
Jul 21, 2025

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit - GlobeNewswire Inc.

Jul 21, 2025
pulisher
Jul 21, 2025

UroGen Pharma Ltd. Stock Analysis and ForecastFree High-Return Strategy Alerts - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

What analysts say about UroGen Pharma Ltd. stockTremendous growth potential - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

UroGen Pharma Announces Data Of Phase 2b Of Bladder Cancer Study - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

UroGen Pharma (URGN) Reports Long-term Results for Bladder Cance - GuruFocus

Jul 21, 2025
pulisher
Jul 21, 2025

UroGen’s bladder cancer drug shows durable response in long-term study - Investing.com Australia

Jul 21, 2025
pulisher
Jul 21, 2025

UroGen Pharma Announces Long-Term Efficacy Results of ZUSDURI for Non-Muscle Invasive Bladder Cancer in Clinical Genitourinary Cancer Journal - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

UroGen Announces Five-Year Long-Term Extension Study of the - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

Breakthrough: New Bladder Cancer Treatment Maintains Effectiveness for 3.5 Years Without Surgery - Stock Titan

Jul 21, 2025
pulisher
Jul 20, 2025

What drives UroGen Pharma Ltd. stock priceBreakthrough financial growth - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

Is UroGen Pharma Ltd. a good long term investmentFree Stock Selection - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

2025-07-20 | URGN Shareholders Have Opportunity to Lead UroGen Pharma Ltd. Class Action LawsuitContact Bronstein, Gewirtz and Grossman, LLC Today! | NDAQ:URGN | Press Release - Stockhouse

Jul 20, 2025
pulisher
Jul 19, 2025

UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors - GlobeNewswire

Jul 19, 2025
pulisher
Jul 19, 2025

Urogen Pharma (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts - Defense World

Jul 19, 2025
pulisher
Jul 18, 2025

UroGen Bets Big On Gel-Based Cancer Treatments - Finimize

Jul 18, 2025
pulisher
Jul 17, 2025

URGN Class Action News: UroGen Pharma Ltd. Investors with - GlobeNewswire

Jul 17, 2025
pulisher
Jul 17, 2025

2025-07-17 | URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:URGN | Press Release - Stockhouse

Jul 17, 2025
pulisher
Jul 16, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming DeadlinesURGN - ETX View

Jul 16, 2025
pulisher
Jul 15, 2025

UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

What makes UroGen Pharma Ltd. stock price move sharplyBreakout Setup Scanner - beatles.ru

Jul 15, 2025
pulisher
Jul 14, 2025

2025-07-14 | URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! | NDAQ:URGN | Press Release - Stockhouse

Jul 14, 2025
pulisher
Jul 13, 2025

What UroGen Pharma Ltd.'s (NASDAQ:URGN) 84% Share Price Gain Is Not Telling You - 富途牛牛

Jul 13, 2025
pulisher
Jul 12, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Jul 12, 2025
pulisher
Jul 12, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm - GlobeNewswire

Jul 12, 2025
pulisher
Jul 12, 2025

Urogen Pharma's (URGN) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Jul 12, 2025
pulisher
Jul 11, 2025

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or - GlobeNewswire

Jul 11, 2025
pulisher
Jul 09, 2025

UroGen bladder cancer drug mitomycin wins FDA approval - MSN

Jul 09, 2025
pulisher
Jul 09, 2025

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - 富途牛牛

Jul 09, 2025
pulisher
Jul 08, 2025

UroGen Pharma stock holds Buy rating at H.C. Wainwright on Phase 3 trial progress By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

UroGen Pharma stock holds Buy rating at H.C. Wainwright on Phase 3 trial progress - Investing.com India

Jul 08, 2025
pulisher
Jul 08, 2025

UroGen concludes enrolment in Phase III trial of UGN-103 for bladder cancer - Yahoo Finance

Jul 08, 2025
pulisher
Jul 07, 2025

Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking - simplywall.st

Jul 07, 2025
pulisher
Jul 07, 2025

URGN: Analyst Reiterates Buy Rating with $25 Price Target | URGN Stock News - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen completes enrollment in phase 3 bladder cancer trial By Investing.com - Investing.com India

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | URGN Stock New - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen completes enrollment in phase 3 bladder cancer trial - Investing.com

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen Pharma Completes Patient Enrollment in Phase 3 UTOPIA Trial for UGN-103 in Bladder Cancer Treatment - Nasdaq

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times

Jul 07, 2025
pulisher
Jul 07, 2025

Breakthrough Bladder Cancer Drug Advances: 99 Patients Enrolled in Phase 3 Trial of Next-Gen Treatment - Stock Titan

Jul 07, 2025
pulisher
Jul 06, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen ... - Bluefield Daily Telegraph

Jul 06, 2025
pulisher
Jul 06, 2025

UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer - MSN

Jul 06, 2025
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):